What the FDA labels say about taking them together
Moxifloxacin and tetrabenazine
Tetrabenazine's FDA label of November 29, 2019 names moxifloxacin in its drug interactions section; the moxifloxacin labels PlainMeds reads (3) do not name tetrabenazine.
Check it at the source: the moxifloxacin FDA label on DailyMed (effective March 17, 2026, Macleods Pharmaceuticals Limited); the tetrabenazine FDA label on DailyMed (effective November 29, 2019, Oceanside Pharmaceuticals).
What does the moxifloxacin label say about tetrabenazine?
Moxifloxacin's label (effective March 17, 2026) and its 2 other brand-application labels do not name tetrabenazine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Moxifloxacin), Macleods Pharmaceuticals Limited, effective March 17, 2026 (SPL set 182ecd0f-714f-42f0-9b16-fb604cf15786), via openFDA; the full label on DailyMed
What does the tetrabenazine label say about moxifloxacin?
Tetrabenazine label, drug interactionsTetrabenazine tablets cause a small prolongation of QTc (about 8 msec), concomitant use with other drugs that are known to cause QTc prolongation should be avoided, these including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval.
Tetrabenazine label, warnings and precautionsThe use of tetrabenazine tablets should be avoided in combination with other drugs that are known to prolong QTc, including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval [see Drug Interactions ( 7.5 )].
Source: FDA drug label (tetrabenazine), NDA021894 (Bausch), as published by Oceanside Pharmaceuticals, effective November 29, 2019 (SPL set 5867189c-17bd-4e70-a079-c4730f9950d1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Moxifloxacin | Tetrabenazine | |
|---|---|---|
| Labeled for | Bacterial infections | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.60 per mL 0.5% eye drops | $0.702 per tablet 12.5 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once